Top 10 Performing Stocks To Buy For 2018


I don’t know if the bull market in bonds is over or not, and nor do I care. I’m not in the business of playing Captain Prediction. I trade the markets that are in front of me, using my data-dependent 3G investing framework, explains Landon Whaley, editor of The Whaley Report.

As we begin 2017, all three gravities — fundamental, quantitative, and behavioral — are signaling that long-dated U.S. Treasuries will be one of the best short opportunities of the next year.


Because it moves in the opposite direction of long-dated Treasuries and it’s leveraged, the ProShares UltraShort 20+ Year Treasury ETF (TBT) will be one of the best-performing fixed income ETFs in 2017.

Fundamentally, U.S. Treasuries are facing a three-headed hydra, with U.S. growth accelerating alongside a stronger U.S. dollar and U.S. yields that are on the come.

The last time this hydra showed itself was during 2013, when long-dated Treasuries lost approximately 14% in nine months, while TBT gained 19%.

Top 10 Performing Stocks To Buy For 2018: Medivation Inc.(MDVN)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…

  • [By Ben Levisohn]

    RBC’s Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer’s (PFE) purchase of Medivation (MDVN):

    Scott Eisen/Bloomberg News

    We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock. The only way for us to get to $81.50 (or even to $60-$70/share) would have been to assign very significant value to talazoparib. And we could not do that given the amount of available clinical evidence.Medivation shareholders who held on to their shares past the $50′s, did just that, were proven right and are now rewarded for it, since they believed that someone would be willing to pay for this asset just months ahead of Phase III data. The key question is why would a company be willing to part with what they claim/think may be a multibillion dollar drug that works in multiple cancers. We believe the obvious answer is because they’re smart and understand drug development risk better than most. We’ll know in a matter of months whether Pfizer/Medivation is like Amgen (AMGN)-Onyx (carfilzomib) or not.

  • [By Lisa Levin]

    Shares of Medivation Inc (NASDAQ: MDVN) got a boost, shooting up 24 percent to $46.35 amid word of a new report from Bloomberg, saying the company is working with bankers to defend itself against preliminary interest of a takeover. However, Reuters separately reported the company is working with JPMorgan to handle interest from other companies, but said Medivation has no interest in selling itself.

  • [By Ben Levisohn]

    Medivation (MDVN) has soared 20% to $80.41 after agreeing to be purchased for $14 billion, or $81.50 a share, by Pfizer (PFE). Pfizer has declined 0.7% to $34.75.

  • [By Ben Levisohn]

    Reports suggest that Gilead Sciences (GILD) and Celgene (CELG) have joined the bidding process forMedivation (MDVN), one that already includes (maybe) Amgen (AMGN), and of course Sanofi (SNY), which is trying to throw out Medivation’s board. Of the three biotech giants, Citigroup’s Robyn Karnauskas and team argue that Amgen is best positioned to win the battle. They explain why:

Top 10 Performing Stocks To Buy For 2018: General Growth Properties, Inc.(GGP)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was GGP Inc. (NYSE: GGP) which jumped about 4.7% to $22.62. The stocks 52-week range is $21.05 to $32.10. Volume was roughly 14.5 million which is above the daily average of around 5.3 million shares.

  • [By Paul Ausick]

    GGP Inc. (NYSE: GGP) posted a new 52-week low of $21.05 on Wednesday, down about 8.6% from Tuesday’s closing price of $23.04. The stock’s 52-week high is $31.35. Volume totaled around 17 million shares, well over double the daily average of around 6.5 million. The REIT missed revenue estimates this morning.

  • [By Paul Ausick]

    GGP Inc. (NYSE: GGP) posted a new 52-week low of $21.05 on Monday, down 1.5% compared with Friday’s closing price of $21.37. The stock’s 52-week high is $32.10. Volume of around 13 million shares was more than double the daily average of around 5.3 million shares. The company slipped after announcing earnings this morning but is on a pace to close the day up more than 4.5%.

Top 10 Performing Stocks To Buy For 2018: Apple Hospitality REIT, Inc.(APLE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Monday.

    AptarGroup, Inc. (NYSE: ATR) – $0.3200 dividend, 1.6780 percent yield. AptarGroup reported weaker-than-expected Q3 results on Thursday. Fidelity Southern Corporation (NASDAQ: LION) – $0.1200 dividend, 2.6359 percent yield. The company, based in Atlanta, Georgia, provides financial products and services for customers. Apple Hospitality REIT Inc (NYSE: APLE) – $0.1000 dividend, 6.5826 percent yield. Apple Hospitality REIT, based in Richmond, Virginia, operates as a subsidiary of Apple REIT Companies. Targa Resources Corp (NYSE: TRGP) – $0.9100 dividend, 7.7299 percent yield. The Houston, Texas-based company provides midstream natura

Top 10 Performing Stocks To Buy For 2018: Live Nation Entertainment, Inc.(LYV)


Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For his “Executive Decision” segment, Cramer checked in with Michael Rapino, president and CEO of Live Nation Entertainment (LYV) , a stock that’s up 44% since Cramer last spoke with him a little more than a year ago but also one that fell 3% in today’s session on what appeared to be solid quarterly results.

Top 10 Performing Stocks To Buy For 2018: International Speedway Corporation(ISCA)


Advisors’ Opinion:

  • [By Monica Gerson]

    International Speedway Corp (NASDAQ: ISCA) is projected to report its quarterly earnings at $0.41 per share on revenue of $146.09 million. International Speedway shares declined 1.65 percent to close at $36.26 yesterday.

  • [By Monica Gerson]

    International Speedway Corp (NASDAQ: ISCA) is estimated to report its quarterly earnings at $0.41 per share on revenue of $146.09 million.

    Mitcham Industries, Inc. (NASDAQ: MIND) is projected to post a quarterly loss at $0.36 per share on revenue of $10.99 million.

Top 10 Performing Stocks To Buy For 2018: QuickLogic Corporation(QUIK)


Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    QuickLogic Corporation (NASDAQ: QUIK) was down, falling around 10 percent to $2.10. QuickLogic reported a $15 million share offering.

    Commodities

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%


    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

Top 10 Performing Stocks To Buy For 2018: EnLink Midstream Partners, LP(ENLK)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    EnLink Midstream Partners (ENLK) is sponsored by independent oil and gas exploration giant Devon Energy (DVN), the owner of this acreage.

    These basins offer superior economics and EnLink’s close relationship with Devon provides leveraged exposure to the upstream operator’s accelerating activity in these plays.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Shoe Carnival, Inc.(SCVL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shoe Carnival, Inc. (NASDAQ: SCVL) was down, falling around 13 percent to $26.45 after the company reported weak earnings for its third quarter and lowered its annual outlook.

Top 10 Performing Stocks To Buy For 2018: Actinium Pharmaceuticals, Inc.(ATNM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.

    Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.

Leave a Reply

Your email address will not be published. Required fields are marked *